17 citations
,
November 2009 in “Dermato-endocrinology” Medium-dose prednisolone pulse therapy is effective and safe for multifocal alopecia areata but not for more severe forms.
Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.
April 2023 in “Australasian Journal of Dermatology” May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
136 citations
,
January 2013 in “International Journal of Trichology”
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
February 2026 in “Dermatology and Therapy” Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.
9 citations
,
March 2023 in “GeroScience” 3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
8 citations
,
December 2021 in “BMJ neurology open” Sodium selenate was found to be safe and possibly slows Alzheimer's progression, but more research is needed.
1 citations
,
December 2020 in “Medical lasers” The laser therapy device effectively increased hair growth in people with androgenetic alopecia.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
September 2017 in “Journal of Investigative Dermatology” RCS-01 is safe and may help rejuvenate aging skin.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery” 1 citations
,
April 2008 in “Progrès en Urologie” Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
1 citations
,
March 2023 in “SKIN The Journal of Cutaneous Medicine” 9 citations
,
April 2024 in “The Oncologist” Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
September 2023 in “Journal of the American Academy of Dermatology” Oral difelikefalin significantly reduces itch in notalgia paresthetica.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
October 2021 in “Dermatology reports” The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.
January 2002 in “Journal of Clinical Dermatology”
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
14 citations
,
January 2001 in “Current Treatment Options in Oncology” Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
January 2022 in “Turk Dermatoloji Dergisi” Topical procyanidin B2 significantly increases hair count and is a safe treatment for male pattern baldness.
12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
January 2012 in “Zhongguo quanke yixue” The treatment was effective and tolerable for advanced gastric cancer.
The treatment showed promising hair regrowth in advanced-stage hair loss.